Key Details
Price
$7.71Annual ROE
-4.98%Beta
0.27Events Calendar
Next earnings date:
Mar 14, 2025Recent quarterly earnings:
Oct 24, 2024Recent annual earnings:
Mar 14, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Pharming Group N.V. (NASDAQ:PHAR ) Q3 2024 Earnings Conference Call October 24, 2024 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Sushila Hernandez - Kempen Joe Pantginis - H.C.
Pharming Group NV (NASDAQ:PHAR ) Q2 2024 Earnings Conference Call August 1, 2024 7:30 AM ET Company Participants Sijmen de Vries - CEO & Executive Director Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Sushila Hernandez - Van Lanschot Kempen Jeff Jones - Oppenheimer Alistair Campbell - RBC Capital Markets Simon Scholes - First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen; I'm here. Next slide, please.
Pharming Group N.V. (NASDAQ: PHAR) will be hosting its Q1 2024 Earnings Conference Call on May 8, 2024 at 7:30 AM ET. The company's Executive Director and CEO, Sijmen de Vries, along with Chief Commercial Officer Stephen Toor, Chief Medical Officer Anurag Relan, and Chief Financial Officer Jeroen Wakkerman will be participating. Conference call participants include Christian Glennie from Stifel, Sushila Hernandez from Van Lanschot Kempen, and Joe Pantginis from H.C.
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average.
Pharming Group NV is a biotechnology firm known for its unique approach to addressing rare and genetic diseases. The company's financials show growth in revenue, primarily driven by strong sales of their leading therapy, Ruconest. Pharming's expansion into organ transplantation fields adds a new dimension to their growth prospects, but challenges remain in gaining acceptance and assessing the impact on their income.
LEIDEN, The Netherlands , Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September: 2023 Wells Fargo Healthcare Conference, Boston, September 6-8 Sijmen de Vries, Chief Executive Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Thursday, September 7 at 16:30 ET/22:30 CET.
Pharming Group N.V. (NASDAQ:PHAR ) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Anurag Relan - Chief Medical Officer Stephen Toor - Chief Commercial Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Christian Glennie - Stifel Joseph Pantginis - H.C.
Pharming Group N.V. (OTCPK:PHGUF) Q2 2023 Earnings Conference Call August 3, 2023 7:30 AM ET Company Participants Sijmen de Vries - CEO Anurag Relan - CMO Stephen Toor - CCO Jeroen Wakkerman - CFO Conference Call Participants Christian Glennie - Stifel Joe Pantginis - H.C.
LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
Pharming Group N.V. (OTCPK:PHGUF) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Stephen Toor – Chief Commercial Officer Jeroen Wakkerman – Chief Financial Officer Conference Call Participants Alistair Campbell – RBC Sushila Hernandez – VLK Simon Scholes – First Berlin Sijmen de Vries Good morning or good afternoon, ladies and gentlemen.
FAQ
- What is the primary business of Pharming Group NV?
- What is the ticker symbol for Pharming Group NV?
- Does Pharming Group NV pay dividends?
- What sector is Pharming Group NV in?
- What industry is Pharming Group NV in?
- What country is Pharming Group NV based in?
- When did Pharming Group NV go public?
- Is Pharming Group NV in the S&P 500?
- Is Pharming Group NV in the NASDAQ 100?
- Is Pharming Group NV in the Dow Jones?
- When was Pharming Group NV's last earnings report?
- When does Pharming Group NV report earnings?